P-glycoprotein (P-gp), an ATP-driven efflux pump in the blood-brain barrier, has a major impact on the delivery of antidepressant drugs in the brain. Genetic variants in the gene ABCB1 encoding for P-gp have inconsistently been associated with adverse effects. In order to resolve these inconsistencies, we conducted a study in a large cohort of patients with major depressive disorder with the aim to unravel the association of ABCB1 variants with adverse effects of antidepressants and in particular with selective serotonin reuptake inhibitors (SSRIs), which display affinity as substrate for P-gp. The Netherlands Study of Depression and Anxiety (NESDA) study was used as a clinical sample. For 424 patients data were available on drug use, side effects. We selected six ABCB1 gene variants (1236T4C, 2677G4T/A, 3435T4C, rs2032583, rs2235040 and rs2235015) and analyzed them for association with adverse drug effects using multinomial regression analysis for both single variants and haplotypes. We found a significant association between the number of SSRI-related adverse drug effects and rs2032583 (P ¼ 0.001), rs2235040 (P ¼ 0.002) and a haplotype (P ¼ 0.002). Moreover, serotonergic effects (sleeplessness, gastrointestinal complaints and sexual effects) were significantly predicted by these variants and haplotype (P ¼ 0.002/0.003). We conclude that adverse drug effects with SSRI treatment, in particular serotonergic effects, are predicted by two common polymorphisms of the ABCB1 gene.
INTRODUCTION
One of the major problems with pharmacotherapy of major depressive disorder is the lack of predictive clinical variables in the occurrence of unpredictable adverse drug reactions, often leading to a prolonged treatment course. An important aspect in this regard is the ability of a drug to pass the blood-brain barrier.
P-glycoprotein (P-gp) is an ATP-driven efflux pump, predominantly located at the luminal side of the brain capillaries.
1 P-gp has an unusually broad capacity to recognize and expel hundreds of molecules from the brain, including many antidepressant drugs. 2 The processes involved often exhibit considerable interindividual variability, which may be genetically determined. P-gp is a member of the ATP-binding cassette superfamily and is encoded by the ABCB1 gene, formerly denoted as MDR1 (multi-drug resistance gene 1).
Animal studies have shown that penetration of several antidepressants depends on the functionality of P-gp at the blood-brain barrier. 3--6 By affecting plasma levels and intracerebral concentration, altered P-gp function or expression may cause adverse drug effects and ultimately influence therapeutic response.
Most studies that analyzed the relation of ABCB1 gene variants with antidepressants have focused on treatment response, with contradictory results. 7--13 Analysis of antidepressants related adverse drug effects in relation to ABCB1 polymorphisms has not been studied extensively so far. Of the three studies to date, one study focused on a single-drug effect (postural hypotension in nortriptyline use (n ¼ 8) in a relatively small sample (n ¼ 78). 14 In another small sample study (n ¼ 55)
antidepressant-induced switch to mania was studied in 26 users of various antidepressants, without taking account of the differential affinity of antidepressants for the P-gp pump. 15 Peters et al. 16 used a large sample (STAR*D, n ¼ 565) of major depressive disorder patients using citalopram and found no association between three single-nucleotide polymorphisms (SNPs) (3435C4T, 2677G4T or 1236C4T) and 'tolerance' to citalopram. 'Tolerance' was considered when subjects continued with citalopram until the end of study period while patients who left the study at any time due to side effects, were defined as 'intolerant'.
Conflicting results may result from small sample sizes and thus limited statistical power. The present study uses data from a Dutch cohort of 424 depressed patients using selective serotonin reuptake inhibitor (SSRI), and examines whether related adverse side effects are associated with ABCB1 gene polymorphisms.
MATERIALS AND METHODS

NESDA sample
NESDA is a longitudinal, naturalistic cohort study examining the course and consequences of depressive and anxiety disorders. The collection and genotyping of the NESDA sample has been described elsewhere. 17 In brief, 2981 participants were recruited through mental health care organizations (n ¼ 807), the community setting (n ¼ 564) and primary care (n ¼ 1610). They were assessed using the Composite Interview Diagnostic Instrument to diagnose depressive and anxiety disorders according to the Diagnostic and Statistical Manual of Mental Disorders---Fourth Edition. The interview also provided information on age of onset, number of major depressive disorder episodes and specific symptoms of depression. At baseline, detailed assessment was made of psychopathology using different inventories and scales. Many other data were collected including sociodemographic data and health indicators.
At the 2-year follow-up assessment phenotypic data concerning course of the current or previous depressive episodes were gathered. Medication use was assessed based on drug container inspection of drugs used and coded using the ATC (Anatomical Therapeutic Chemical) classification. 18 Use of antidepressants was considered when taken at least 50% of the time and included SSRIs (ATC-code N06AB). Antidepressants were categorized into SSRIs with known substrate affinity for P-gp (that is, citalopram, paroxetine, venlafaxine, fluvoxamine and sertrailine). All other non-SSRI antidepressants were left out of the analysis (that is, tricyclic antidepressants, St John's Wort, lithium, MAO inhibitors) as well as SSRIs without affinity for P-gp, or without compelling evidence for the opposite (that is, fluoxetine, bupropion, nefazodone, trazodone, mirtazapine and duloxetine,).
2,4--6,19--21 Subjects using comedication with a strong modulatory effect on P-gp function, such as calcium-blocking agents, protease inhibitors, cardiac glycosides, ketoconazole, methotrexate and quinidine, 22, 23 were excluded from the analysis.
Adverse drug effects
The questionnaire on 'side effect of psychotropic medication' provided a self-reported inventory of psychotropic medication (type, frequency, dosage, and duration), treatment response and adverse side effects data. Adverse drug reactions were measured at the 1-year and 2-year follow-up. adverse drug reactions were reported as 'present' or 'absent'. The ASEC-12 self report questionnaire, a short version of the Antidepressant Side Effect Checklist, was constructed for NESDA. Recently, the ASEC-21 has been validated against the UKU Side-Effect Rating Scale, a semi-structured interview by a health professional. 24, 25 The ASEC-12 specifically asks for the presence of 12 adverse drug reactions, which have been related to antidepressants: sleeplessness, sleepiness during day time, restlessness, twitching/muscle cramps, dry mouth, transpiration, sexual side effects, nausea, constipation, diarrhea, weight gain and dizziness). In addition, participants were asked to add other side effects, not covered in the inventory. Side effects were also grouped and defined as either 'anticholinergic' (that is, restlessness, constipation and dry mouth), 'serotonergic' (that is, diarrhea, sexual side effects, twitching, nausea and sleeplessness) or 'histaminergic' (sleepiness during the day, weight gain).
Antidepressants were categorized into SSRIs with known substrate affinity for P-gp (that is, citalopram, paroxetine, venlafaxine, fluvoxamine and sertraline). All other non-SSRI antidepressants were left out of the analysis (that is, tricyclic antidepressants, St John's Wort, lithium, MAO inhibitors) as well as SSRI's without affinity for P-gp, or without compelling evidence for the opposite (that is, fluoxetine, bupropion, nefazodone, trazodone, mirtazapine and duloxetine).
2,4--6,19--21 Sertraline was categorized as a SSRI with P-gp affinity based on high in vitro affinity. 21 SNP selection and genotyping A selection of six SNPs was made on the basis of positive reports in the existing literature. 8, 10, 26, 27 This included the three common coding SNPs 3435C4T (rs1045642), 2677G4T/A (rs2032582) and 1236T4C (rs1128503) and three noncoding SNPs (rs2235015, rs2032583 and rs2235040) that were associated with treatment response to antidepressants. 11, 12 The genotypic data were obtained from the genome-wide association study. 28 These data were subjected to rigorous quality control criteria. 29 None of the six SNPs was directly genotyped, but estimated genotype probabilities were obtained through imputation. 30 The quality of imputation was good (P ¼ 0.93) for 3435C4T and excellent (P ¼ 0.99--1.00) for the other SNPs. More details are presented in Table 1 .
Covariates and exclusion criteria
We excluded 16 participants who used medication with a strong inhibitory effect on P-gp function (calcium-blocking agents, protease inhibitors, cardiac glycosides, ketoconazole, methotrexate and quinidine) 22, 23 from the analysis. The group of subjects using statin drugs (for example, simvastatin, ATC codes: C10AA01-C10BA02)) (n ¼ 42) was considered large enough to include statin use in all analyses as a covariate. For the selected SSRIs, a derived daily dose was calculated by dividing the participant's mean daily dose by the daily dose recommended by the World Health Organization. 18 This variable was included as covariate in the analysis in order to adjust for medication dosage effects. The variables 'age', 'gender' were also included in each analysis as covariates, as these variables have an impact on the side effect profile of antidepressants. 31, 32 Statistical analysis Hardy--Weinberg equilibrium was evaluated by w 2 statistics. No SNPs were found to violate Hardy--Weinberg equilibrium using a Bonferroni-corrected threshold. Multinomial logistic regression analysis was conducted for SSRIrelated adverse effects divided in three groups, namely 0, 1--3 and 4--12 adverse effects, with allele dosages of the SNPs as independent variable.
A multinomial analysis was also done for aggregated groups of adverse drug effects (that is, serotonergic, anticholinergic and histaminergic (see above)). Likewise, these variables were recoded into multinomial variables (0, 1 or 2 or more adverse effects). Furthermore, all adverse drug effects were tested as dichotomous variable (absent or present) in a logistic regression analysis, on possible associations with the polymorphisms that had shown an effect in the multinomial analysis. The analyses were carried out for the group of SSRI users (SSRIs with affinity for P-gp), as well as for 
Follow-up analysis with only the two SNPs that had shown an association in the multinomial analysis, were carried out for the three aggregated groups (that is, anticholinergic, serotonergic and histaminergic) and 12 separate adverse drug effects. The (multinomial) regression analyses for the variables 'histaminergic' and 'serotonergic' was done with dichotomous variables, because too few cases (4 and 6) remained in the 2 þ group, making the validity of the model uncertain.
Frequencies of the haplotypes containing the six SNPs were estimated using the following randomization procedure. For each individual and each SNP a genotype was assigned randomly five times from its imputed genotype probability distribution. Next for each randomized set the software package PHASE was used to estimate haplotype probabilities for each individual. 33, 34 The haplotype probabilities were aggregated and frequencies of the 64 possible haplotypes were calculated. 33, 34 For each of the four haplotypes with a frequency of 410%, haplotype dosage (that is, the estimated number of haplotypes in an individual) was determined for every individual using the estimated haplotype probabilities like is done for Haplotype Trend Regression analysis. 35 Haplotype analysis was performed using multinomial or logistic regression analysis similar to the single SNP analyses described earlier. In addition, we used these frequencies to estimate linkage disequilibrium of each pair of SNPs. Given the strong linkage disequilibrium for two SNP pairs (2677G4T/A--1236T4C: r 2 ¼ 0.88 and rs2235040--rs2032583: r 2 ¼ 0.98), the significance threshold was set at 0.0125 as a result of a Bonferroni correction for multiple testing. Statistical analyses were conducted using SPSS software 
RESULTS
The sample consisted of 504 SSRI users, of which 347 were current users and 157 had used an SSRI before. In all, 16 were excluded because of use of comedication with a strong inhibitory effect on P-gp function. For 64 cases genotype or interview data were incomplete, and these were also excluded from the analysis. The remaining 424 cases were used for analysis. Details of the study sample are given in Table 2 .
Adverse drug effects For SSRI use, the most reported side effects were sexual dysfunction (19.0%), dry mouth (18.8%), sleepiness during the day (18.8%), weight gain (17.7%) and profuse sweating (14.5%). Gastrointestinal side effects were relatively infrequent: diarrhoea (3.8%), nausea (10.1%) and constipation (8.9%). Other reported side effects in the inventory were dizziness (14.1%), sleeplessness (7.5%), restlessness (6.5%) and muscle spasms or twitching (8.7%). For the SSRI users (n ¼ 424), two SNPs were significantly associated with the number of side effects (rs2235040A: P ¼ 0.002; OR ¼ 2.29; and rs2032583C: P ¼ 0.001, OR ¼ 2.41), see Table 3 . Sex and age had no significant effect as covariate in these analyses. Statin use and antidepressant dosage (derived daily dose) had no significant effect in any of the analyses.
Of the three groups of aggregated side effects, 'anticholinergic' 'serotonergic' and 'histaminergic', the two SNPs were also significantly associated with 'few' serotonergic effects: rs2235040A (P ¼ 0.003; OR ¼ 1.85) and rs2032583C (P ¼ 0.002; OR ¼ 1.95). Male gender was strongly associated (OR ¼ 1.97; P ¼ 0.003) with 'serotonergic' effects (containing the variable 'sexual effects'). No association was found with 'multiple' serotonergic effects, owing to the fact that this group contained only 16 subjects. For the association between the two SNPs (rs2235040A and rs2032583C) and 'multiple' anticholinergic effects a significant trend (P ¼ 0.015 for both) was seen. No associations were found with 'histaminergic' effects.
The two SNPs were also evaluated as predictors of each single side effect in adjusted logistic regression analyses. The variable 'sleepless' was strongly associated with rs2235040A (P ¼ 0.0004; OR ¼ 1.85) and rs2032583C (P ¼ 0.0004; OR ¼ 2.90). No other significant associations were seen for any of the single side effects. Male gender was significantly associated with the occurrence of SSRI-related sexual side effects (P ¼ 0.0003; OR ¼ 2.63). There was a nonsignificant association for use of statins (P ¼ 0.064) for the variable 'weight gain'.
The two mostly used SSRIs in this study, paroxetine (n ¼ 151) and citalopram (n ¼ 106), were separately tested for possible gene related side effects. For both antidepressants, no significant associations between SNPs and adverse effects were found (citalopram data not shown).
Haplotype analysis Of the 64 haplotypes, covering the six SNPs used in the analysis (3435C4T-2677G4T/A-1236T4C-rs2235015-rs2032583-rs2235040), we analyzed the four with a frequency higher than 10%:
T-T-T-G-T-G (39%), T-G-C-G-T-G 14%, C-G-C-T-C-A, 13% and C-G-C-G-T-G, 22%.
The haplotype C-G-C-T-C-A showed similar P-values for all the significant associations that we observed earlier for the two SNPs (see Table 3 ).
DISCUSSION
Our results suggest that some ABCB1 polymorphisms might predict adverse side effects related to the SSRIs that have affinity for P-gp. Of the six SNPs tested, two intronic SNPs (rs2235040A and rs2032583C) and the haplotype C-G-C-T-C-A were significant predictors for the number of adverse side effects, and were in particular associated with serotonergic (especially sleeplessness) effects. This is of high interest as the association between side effects and the genetic variants of P-gp reflects SSRI transport into the brain. As central side effects can only occur at higher cerebral drug levels, they are indirect evidence for P-gp transport processes at the blood-brain barrier. So far, literature has presented efficacy as proof of a sufficient drug transport. Here, the same genetic variants have been found as predictive. Thus, there are two different and independent methods (efficacy, side effects) of detecting SSRI transport at the blood-brain barrier.
In our study, the two SNPs (rs2235040 and rs2032583) were in near complete linkage disequilibrium, thus representing the same 1.14 ± 0.38
Abbreviations: DDD, derived-daily dose; P-gp, P-glycoprotein; SSRI, selective serotonin reuptake inhibitor.
ABCB1 polymorphisms influence tolerance to SSRIs OL de Klerk et al information Both SNPs have been associated with higher treatment response on antidepressants, that are transported by P-gp, in contrast to mirtazapine, which is not a substrate for P-gp. 11, 12 In these studies, the T-carriers of rs2032583 were associated with poor treatment response, which may correspond with a higher level of adverse effects, as we found for the rs2032583 C-allele.
Neither our study nor previous ones, 11, 12, 16 found an effect of the SNPs 1236C4T, 2677G4T/A and 3435C4T. These three SNPs have been the focus of many pharmacokinetic and disease-related studies, as these are common SNPs in the coding region of the ABCB1 gene. 36 Studies on genetic associations of these SNPs with clinical phenotypes have largely been inconsistent. 9, 37 The 1236C-2677G-3435C haplotype is one of the most frequently observed in most populations. 37 In fact, the C-G-C haplotype has been connected to altered P-gp functionality in several studies, but ABCB1 haplotype association studies have also been inconclusive so far. 9, 36 In our study the haplotype containing 1236C-2677G-3435C links to the rs2032583C and rs2235040A allele and both these single SNPs and the total haplotype of SNPs were associated with adverse drug effects. This implies that the haplotype association that was observed previously might be caused by the association of the two single SNPs rs2032583 and rs2235040, which are in almost complete linkage disequilibrium with each other. The intronic SNPs rs2032583 and rs2235040 are noncoding SNPs, but might be linked to another functional variant. However, in the absence of replication of the findings in this report, and in the light of the many controversies on ABCB1 related gene effects so far, the conclusions need to be interpreted with care. A replication study was, however, not feasible, as our sample is unique in this respect. Another reason for cautiousness is the notion that not all adverse effects are necessarily drug-related effects. As we know from placebo controlled drug trials, adverse effects are also reported in the placebo group. Inclusion of a placebo arm could exclude type I error (a false-positive result). The NESDA study was, however, not set up as a pharmacogenetic study.
One of the limitations of this study is the fact we have not controlled for all comedication. Many drugs have shown to possess some inhibitory or inductory properties in vitro, such as statins, 38 antipsychotics or antidepressants, 6 but their impact on P-gp function in vivo may be clinically irrelevant. 5, 6 Therefore, we only excluded comedication, for which clear evidence was available, with respect to P-gp inhibitory or inductory properties of a drug, for example, antiretroviral or other immunosuppressive agents. 39 We controlled for statin use, because this group was considered large enough to include in the analyses as a covariate. In none of the analyses, however, any interaction was seen. Interaction with other comedication can, however, not be excluded. And connecting to the previous paragraph, the use of multiple medications can further trouble the interpretation of SSRI related drug effects, despite the use of a drug class specific questionnaire.
The gene effect that we found for the SSRIs with affinity for P-gp may not be valid for each SSRI to the same degree. The selected SSRIs have shown to have comparable substrate properties 2,4--6 and moreover, substrate specific in vivo data on P-gp function is lacking. Abbreviations: n.a., not analysed (because of too low numbers); P-gp, P-glycoprotein; SSRI, specific serotonergic reuptake inhibitor. Significance was assessed using multinomial and logistic regression analysis adjusted for sex, age and statin use, and odds ratio's including P-values, are shown for minor allele carrier vs non-carrier. Bold values indicate significant results. *Significant sex effect (see results).
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